lenabasum   Click here for help

GtoPdb Ligand ID: 9772

Synonyms: ajulemic acid | CPL-7075 | CPL7075 | CT-3 | IP-751 | IP751
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Lenabasum (ajulemic acid) is a synthetic derivative of the non-psychoactive cannabinoid THC metabolite 11-nor-9-Carboxy-THC (PubChem CID 108207) [10]. It is a non-selective cannabinoid receptor agonist [5,7]. Lenabasum exhibits potentially useful analgesic and anti-inflammatory actions [3].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 2
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 66.76
Molecular weight 400.26
XLogP 6.96
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCCCCCC(c1cc(O)c2c(c1)OC(C1C2CC(=CC1)C(=O)O)(C)C)(C)C
Isomeric SMILES CCCCCCC(c1cc(O)c2c(c1)OC([C@H]1[C@H]2CC(=CC1)C(=O)O)(C)C)(C)C
InChI InChI=1S/C25H36O4/c1-6-7-8-9-12-24(2,3)17-14-20(26)22-18-13-16(23(27)28)10-11-19(18)25(4,5)29-21(22)15-17/h10,14-15,18-19,26H,6-9,11-13H2,1-5H3,(H,27,28)/t18-,19-/m1/s1
InChI Key YCHYFHOSGQABSW-RTBURBONSA-N
References
1. Burstein S. (2005)
Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials.
AAPS J, 7 (1): E143-8. [PMID:16146336]
2. Burstein SH. (2018)
Ajulemic acid: potential treatment for chronic inflammation.
Pharmacol Res Perspect, 6 (2): e00394. [PMID:29638269]
3. Burstein SH, Karst M, Schneider U, Zurier RB. (2004)
Ajulemic acid: A novel cannabinoid produces analgesia without a "high".
Life Sci, 75 (12): 1513-22. [PMID:15240185]
4. Chmiel JF, Flume P, Downey DG, Dozor AJ, Colombo C, Mazurek H, Sapiejka E, Rachel M, Constantine S, Conley B et al.. (2021)
Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis.
J Cyst Fibros, 20 (1): 78-85. [PMID:33011099]
5. Han S, Thatte J, Buzard DJ, Jones RM. (2013)
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
J Med Chem, 56 (21): 8224-56. [PMID:23865723]
6. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. (2003)
Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial.
JAMA, 290 (13): 1757-62. [PMID:14519710]
7. Rhee MH, Vogel Z, Barg J, Bayewitch M, Levy R, Hanus L, Breuer A, Mechoulam R. (1997)
Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase.
J Med Chem, 40 (20): 3228-33. [PMID:9379442]
8. Spiera R, Hummers L, Chung L, Frech TM, Domsic R, Hsu V, Furst DE, Gordon J, Mayes M, Simms R et al.. (2020)
Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis.
Arthritis Rheumatol, 72 (8): 1350-1360. [PMID:32336038]
9. Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M. (2004)
A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis.
Arthritis Rheum, 50 (3): 985-98. [PMID:15022343]
10. Vann RE, Cook CD, Martin BR, Wiley JL. (2007)
Cannabimimetic properties of ajulemic acid.
J Pharmacol Exp Ther, 320 (2): 678-86. [PMID:17105826]